Eli Lilly and Company

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. This approval allows for the use of Jaypirca as a first-line treatment for appropriate patients.

Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.

Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.

Novo Nordisk (NYSE:NVO) faces further pressure in the obesity-drug market after Eli Lilly and Co (NYSE:LLY) reported promising mid-stage data for an experimental treatment that delivered greater weight loss than tirzepatide alone. EloraTZP, a combination of eloralintide and tirzepatide targeting amylin, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways, produced weight loss of up to 23.3% after 48 weeks in overweight or obese patients with type 2 diabetes.